The opioid crisis produced one of the largest litigation windfalls in American legal history. Purdue Pharma, Johnson & Johnson, the three big distributors: the settlements ran into the tens of billions, parceled out to states that were supposed to spend it on addiction treatment. Methadone clinics, naloxone distribution, treatment beds, school prevention programs.
Louisiana just voted to put some of it toward ibogaine research.
- SB 43 funds FDA-regulated clinical trials using opioid litigation settlement money, not a new state appropriation or federal earmark.
- Both chambers voted unanimously. Governor Landry let the clock run out without signing or vetoing. The law takes effect August 1, 2026.
- This is a research program, not a treatment pathway. Trials still need FDA investigational drug authorization and DEA Schedule I permits, and will take years.
- If you need ibogaine now, the answer is still Mexico. This law changes nothing for patients in the next 12 months.
- Louisiana is at least the ninth state with formal legislative action on ibogaine. The count was seven as recently as May.
Both chambers of the state legislature approved Senate Bill 43 in unanimous votes. Not close votes. Not partisan ones. Unanimous. A Republican senator from St. Tammany Parish named Patrick McMath sponsored it. A Republican governor named Jeff Landry received it. And then Landry did something that tells you a lot about where ibogaine sits politically right now: he didn't sign it. He didn't veto it, either. He let the clock run out, which under Louisiana law means the bill takes effect anyway on August 1, 2026, without his name on it.
A unanimous legislature, a governor who wouldn't put his name on it, and a law that takes effect anyway.
So why does any of this matter?
What the law actually does
SB 43 creates a state-run pilot program under the Louisiana Department of Health to fund FDA-regulated clinical trials involving ibogaine, psilocybin, and MDMA. The specific population is people with opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions.
The funding source is the key detail: opioid litigation settlement dollars, not a new budget line item or federal earmark, but money that flowed to Louisiana specifically because the opioid industry destroyed so many Louisiana lives.
There are provisions for academic institutions to partner with pharmaceutical companies: if a drug born from these trials gains FDA approval, 2.5% of net sales goes back to Louisiana. The state also joins a national research consortium that pulls in data from other states with similar programs.
Researchers will still need to go through the FDA's investigational drug process and obtain DEA permission to handle Schedule I substances. What the state is providing is funding and a formal commitment: this is worth investigating.
The money angle
There's a specific irony here that I don't think gets enough attention.
The opioid settlement money came from companies that, in many cases, actively suppressed research into addiction treatments that didn't generate recurring revenue. Ibogaine is a perfect example of this dynamic. It's derived from a plant. It can't be patented in its natural form. The estimated mechanism (resetting opioid receptors, interrupting withdrawal at a neurological level rather than managing it symptom by symptom) doesn't lend itself to a daily pill franchise. So it sat. Research interest came from academic labs and international clinics, not drug companies.
Now some of the money those drug companies paid in settlement is being redirected to study the thing they had no incentive to develop.
Louisiana isn't the first state to find creative funding for ibogaine research. Texas committed $50 million from state appropriations through Senate Bill 2308, matched by federal dollars after President Trump's April 2026 executive order. Mississippi tied its research program to pharmaceutical partnerships. Colorado passed legislation in May establishing up to five research sites through the state's behavioral health administration.
But the settlement angle is different. The opioid crisis is, in a small way, funding its own alternative.
What the governor's non-signature actually means
Governor Landry is a conservative Republican who signed legislation around the same time that makes it a jail offense to smoke marijuana within 2,000 feet of a school. His decision not to sign SB 43 wasn't a principled endorsement of psychedelic medicine.
But he also didn't kill it.
The bill passed unanimously. Killing it would have meant vetoing something every member of his legislature voted for, including members from his own party. The political cost of a veto was higher than the political cost of quietly doing nothing.
The result is a law with a unanimous mandate and a governor who, officially, had nothing to do with it. In the current political environment for psychedelic medicine, that's actually a reasonable description of where things stand nationally: the evidence is compelling enough that elected officials won't say no, but not yet mainstream enough that they'll stand up and say yes.
Trump signed his executive order on psychedelics. He also made sure the press conference included Navy SEALs and combat veterans. The messaging is always: this is for veterans who earned it, not for recreation. Louisiana's legislature made the same framing move. Rep. Neil Riser told the House that "for every soldier killed in action, five commit suicide when they get home," and predicted his colleagues would look back on this vote with pride.
What it means for patients today
Nothing yet, and I want to be straightforward about that.
SB 43 creates a research program, not a treatment pathway. The clinical trials funded under this law will need FDA investigational new drug authorization, DEA Schedule I researcher permits, IRB approval, patient recruitment, and years of execution before any data exists. Even if the trials produce the results the evidence suggests they should, the path from that to an FDA-approved treatment is measured in years, not months.
If you or someone you know needs ibogaine now, the answer is still Mexico. Supervised, medically staffed facilities with cardiac screening and physician oversight (not every clinic, but the right ones). The regulatory progress is real, but it doesn't help you in the next six months.
What Louisiana does change is the political permission structure. Unanimous votes in a Southern Republican legislature tend to move other legislatures. And the use of opioid settlement money creates a funding template other states could copy without new appropriations. North Carolina has a similar bill in committee. Several other states are watching.